Molecular cell biology of apoptosis and necroptosis in cancer

Advances in Experimental Medicine and Biology

Volumn 930, Issue , 2016, Pages

  Dillon, Christopher P ^a   Green, Douglas R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Apoptosis; BCL 2; Cancer; Caspases; Cell death; Immunogenic; Inflammation; Necroptosis; RIPK3

Indexed keywords

CASPASE; CASPASE 2; CASPASE 8; CASPASE 9; PROTEIN KINASE; RECEPTOR INTERACTING SERINE THREONINE PROTEIN KINASE 1; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CYTOKINE; DEATH RECEPTOR; INFLAMMASOME; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RIPK1 PROTEIN, HUMAN; RIPK1 PROTEIN, MOUSE; TUMOR PROTEIN;

APOPTOSIS; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL FUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; CELL DEATH; DEFICIENCY; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NECROSIS; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL DEATH; CYTOKINES; HUMANS; INFLAMMASOMES; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NECROSIS; NEOPLASM PROTEINS; NEOPLASMS; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION;

EID: 84984631773     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-319-39406-0_1     Document Type: Chapter

References (190)

1. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer. 1954;8(1):1-12.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57-70.
4. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231-41.
5. Ashkenazi A, Salvesen G. Regulated cell death: signaling and mechanisms. Annu Rev Cell Dev Biol. 2014;30:337-56.
6. Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differ. 1998;5(12):997-1000.
7. MacKenzie SH, Clark AC. Death by caspase dimerization. Adv Exp Med Biol. 2012;747:55-73.
8. Mace PD, Riedl SJ. Molecular cell death platforms and assemblies. Curr Opin Cell Biol. 2010;22(6):828-36.
9. Tait SW, Green DR. Mitochondrial regulation of cell death. Cold Spring Harb Perspect Biol. 2013;5(9). pii: a008706.
10. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621-32.
11. Chipuk JE, et al. The BCL-2 family reunion. Mol Cell. 2010;37(3):299-310.
12. Llambi F, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44(4):517-31.
13. Honarpour N, et al. Adult Apaf-1-deficient mice exhibit male infertility. Dev Biol. 2000;218(2):248-58.
14. Houde C, et al. Caspase-7 expanded function and intrinsic expression level underlies strainspecific brain phenotype of caspase-3-null mice. J Neurosci. 2004;24(44):9977-84.
15. Leonard JR, et al. Strain-dependent neurodevelopmental abnormalities in caspase-3-deficient mice. J Neuropathol Exp Neurol. 2002;61(8):673-7.
16. Hakem R, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94(3):339-52.
17. Woo M, et al. Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev. 1998;12(6):806-19.
18. Lindsten T, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell. 2000;6(6):1389-99.
19. Takeuchi O, et al. Essential role of BAX, BAK in B cell homeostasis and prevention of autoimmune disease. Proc Natl Acad Sci U S A. 2005;102(32):11272-7.
20. Rathmell JC, et al. Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis. Nat Immunol. 2002;3(10):932-9.
21. Bouillet P, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735-8.
22. Zinkel SS, et al. Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev. 2003;17(2):229-39.
23. Michalak EM, et al. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008;15(6):1019-29.
24. Villunger A, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302(5647):1036-8.
25. Shibue T, et al. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003;17(18):2233-8.
26. Rinkenberger JL, et al. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 2000;14(1):23-7.
27. Veis DJ, et al. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 1993;75(2):229-40.
28. Motoyama N, et al. Massive cell death of immature hematopoietic cells and neurons in Bclx- deficient mice. Science. 1995;267(5203):1506-10.
29. Opferman JT, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307(5712):1101-4.
30. Opferman JT, et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671-6.
31. Dzhagalov I, John AS, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood. 2007;109(4):1620-6.
32. Perciavalle RM, Opferman JT. Delving deeper: MCL-1‘s contributions to normal and cancer biology. Trends Cell Biol. 2013;23(1):22-9.
33. Hildeman D, et al. Apoptosis and the homeostatic control of immune responses. Curr Opin Immunol. 2007;19(5):516-21.
34. Strasser A, et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348(6299):331-3.
35. Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene. 2009;28(9):1274-9.
36. McDonnell TJ, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57(1):79-88.
37. Biswas S, et al. A role for proapoptotic Bax and Bak in T-cell differentiation and transformation. Blood. 2010;116(24):5237-46.
38. Meijerink JP, et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood. 1998;91(8):2991-7.
39. Campbell KJ, et al. Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance. Blood. 2010;116(17):3197-207.
40. Glaser SP, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26(2):120-5.
41. Xiang Z, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest. 2010;120(6):2109-18.
42. Beroukhim R, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899-905.
43. Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta. 2004;1644(2-3):229-49.
44. Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2015;145:76-84.
45. Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22(7):1071-80.
46. Williams MM, Cook RS. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance? Oncotarget. 2015;6(6):3519-30.
47. Fedorov LM, et al. Bcl-2 determines susceptibility to induction of lung cancer by oncogenic CRaf. Cancer Res. 2002;62(21):6297-303.
48. Pena JC, Rudin CM, Thompson CB. A Bcl-xL transgene promotes malignant conversion of chemically initiated skin papillomas. Cancer Res. 1998;58(10):2111-6.
49. Correia C, et al. Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015;1853(7):1658-71.
50. Certo M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351-65.
51. Montero J, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160(5):977-89.
52. Vela L, Marzo I. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr Opin Pharmacol. 2015;23:74-81.
53. Gandhi L, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909-16.
54. Roberts AW, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488-96.
55. Wilson WH, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-59.
56. Kipps TJ, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015:56(10):2826-33.
57. Zhang H, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-51.
58. Merino D, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood. 2012;119(24):5807-16.
59. Souers AJ, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-8.
60. Yecies D, et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115(16):3304-13.
61. Rudin CM, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18(11):3163-9.
62. Varadarajan S, et al. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 2013;20(11):1475-84.
63. Leverson JD, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate ontarget cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015;6, e1590.
64. Varadarajan S, et al. Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner. Oncotarget. 2015;6(14):12668-81.
65. Brumatti G, Ekert PG. Seeking a MCL-1 inhibitor. Cell Death Differ. 2013;20(11):1440-1.
66. Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem. 2014;57(15):6275-88.
67. Walensky LD, et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305(5689):1466-70.
68. Walensky LD, et al. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell. 2006;24(2):199-210.
69. Cohen NA, et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Chem Biol. 2012;19(9):1175-86.
70. LaBelle JL, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest. 2012;122(6):2018-31.
71. Vaillant F, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptorpositive breast cancer. Cancer Cell. 2013;24(1):120-9.
72. Mattoo AR, et al. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics. Clin Cancer Res. 2014;20(21):5446-55.
73. Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat. 2007;10(6):207-17.
74. Besbes S, et al. New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget. 2015;6(15):12862-71.
75. Li H, et al. Activation of caspase-2 in apoptosis. J Biol Chem. 1997;272(34):21010-7.
76. Khar A, et al. Caspase-2/NEDD-2 protease mediates execution of apoptosis in AK-5 tumor cells. Apoptosis. 1997;2(6):494-500.
77. Bouchier-Hayes L, Green DR. Caspase-2: the orphan caspase. Cell Death Differ. 2012;19(1):51-7.
78. Janssens S, Tinel A. The PIDDosome, DNA-damage-induced apoptosis and beyond. Cell Death Differ. 2012;19(1):13-20.
79. Shi M, et al. DNA-PKcs-PIDDosome: a nuclear caspase-2-activating complex with role in G2/M checkpoint maintenance. Cell. 2009;136(3):508-20.
80. Berube C, et al. Apoptosis caused by p53-induced protein with death domain (PIDD) depends on the death adapter protein RAIDD. Proc Natl Acad Sci U S A. 2005;102(40):14314-20.
81. Bouchier-Hayes L, et al. Characterization of cytoplasmic caspase-2 activation by induced proximity. Mol Cell. 2009;35(6):830-40.
82. Bonzon C, et al. Caspase-2-induced apoptosis requires bid cleavage: a physiological role for bid in heat shock-induced death. Mol Biol Cell. 2006;17(5):2150-7.
83. Upton JP, et al. Caspase-2 cleavage of BID is a critical apoptotic signal downstream of endoplasmic reticulum stress. Mol Cell Biol. 2008;28(12):3943-51.
84. Olsson M, Forsberg J, Zhivotovsky B. Caspase-2: the reinvented enzyme. Oncogene. 2015;34(15):1877-82.
85. Thompson R, et al. An Inhibitor of PIDDosome Formation. Mol Cell. 2015;58(5):767-79.
86. Manzl C, et al. Caspase-2 activation in the absence of PIDDosome formation. J Cell Biol. 2009;185(2):291-303.
87. Peintner L, et al. The tumor-modulatory effects of Caspase-2 and Pidd1 do not require the scaffold protein Raidd. Cell Death Differ. 2015;22:1803-11.
88. Sidi S, et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell. 2008;133(5):864-77.
89. Manzl C, et al. Death of p53-defective cells triggered by forced mitotic entry in the presence of DNA damage is not uniquely dependent on Caspase-2 or the PIDDosome. Cell Death Dis. 2013;4, e942.
90. Bergeron L, et al. Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Dev. 1998;12(9):1304-14.
91. Zhang Y, et al. Caspase-2 deficiency enhances aging-related traits in mice. Mech Ageing Dev. 2007;128(2):213-21.
92. Wilson CH, et al. Age-related proteostasis and metabolic alterations in Caspase-2-deficient mice. Cell Death Dis. 2015;6, e1597.
93. Shalini S, et al. Caspase-2 protects against oxidative stress in vivo. Oncogene. 2015;34:4995-5002.
94. Sharma R, et al. Caspase-2 maintains bone homeostasis by inducing apoptosis of oxidativelydamaged osteoclasts. PLoS One. 2014;9(4), e93696.
95. Kumar S. Caspase function in programmed cell death. Cell Death Differ. 2007;14(1):32-43.
96. Manzl C, et al. PIDDosome-independent tumor suppression by Caspase-2. Cell Death Differ. 2012;19(10):1722-32.
97. Dorstyn L, et al. Caspase-2 deficiency promotes aberrant DNA-damage response and genetic instability. Cell Death Differ. 2012;19(8):1288-98.
98. Puccini J, et al. Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice. Proc Natl Acad Sci U S A. 2013;110(49):19920-5.
99. Ho LH, et al. A tumor suppressor function for caspase-2. Proc Natl Acad Sci U S A. 2009;106(13):5336-41.
100. Holleman A, et al. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood. 2005;106(5):1817-23.
101. Terry MR, et al. Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo. Cell Death Differ. 2015;22(5):719-30.
102. Parsons MJ, et al. Genetic deletion of caspase-2 accelerates MMTV/c-neu-driven mammary carcinogenesis in mice. Cell Death Differ. 2013;20(9):1174-82.
103. Dorstyn L, et al. An unexpected role for caspase-2 in neuroblastoma. Cell Death Dis. 2014;5, e1383.
104. Ren K, et al. Tumor-suppressing function of caspase-2 requires catalytic site Cys-320 and site Ser-139 in mice. J Biol Chem. 2012;287(18):14792-802.
105. Thompson R, Eastman A. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. Br J Clin Pharmacol. 2013;76(3):358-69.
106. Dent P, et al. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv. 2011;11(2):133-40.
107. Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther. 2015;149:124-38.
108. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3(9):745-56.
109. Oberst A, et al. Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem. 2010;285(22):16632-42.
110. Walczak H, Sprick MR. Biochemistry and function of the DISC. Trends Biochem Sci. 2001;26(7):452-3.
111. Kallenberger SM, et al. Intra- and interdimeric caspase-8 self-cleavage controls strength and timing of CD95-induced apoptosis. Sci Signal. 2014;7(316):ra23.
112. McStay GP, Salvesen GS, Green DR. Overlapping cleavage motif selectivity of caspases:implications for analysis of apoptotic pathways. Cell Death Differ. 2008;15(2):322-31.
113. Tu S, et al. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol. 2006;8(1):72-7.
114. Pop C, et al. FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem J. 2011;433(3):447-57.
115. Varfolomeev EE, et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity. 1998;9(2):267-76.
116. Gunther C, et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature. 2011;477(7364):335-9.
117. Kovalenko A, et al. Caspase-8 deficiency in epidermal keratinocytes triggers an inflammatory skin disease. J Exp Med. 2009;206(10):2161-77.
118. Kang TB, et al. Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol. 2004;173(5):2976-84.
119. Krajewska M, et al. Neuronal deletion of caspase 8 protects against brain injury in mouse models of controlled cortical impact and kainic acid-induced excitotoxicity. PLoS One. 2011;6(9), e24341.
120. Dillon CP, et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep. 2012;1(5):401-7.
121. Lemmers B, et al. Essential role for caspase-8 in Toll-like receptors and NFkappaB signaling. J Biol Chem. 2007;282(10):7416-23.
122. Salmena L, Hakem R. Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder. J Exp Med. 2005;202(6):727-32.
123. Beisner DR, et al. Cutting edge: innate immunity conferred by B cells is regulated by caspase- 8. J Immunol. 2005;175(6):3469-73.
124. Teitz T, et al. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res. 2013;73(13):4086-97.
125. Teitz T, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med. 2000;6(5):529-35.
126. Ashley DM, et al. Caspase 8 is absent or low in many ex vivo gliomas. Cancer. 2005;104(7):1487-96.
127. Soung YH, et al. CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas. Cancer Res. 2005;65(3):815-21.
128. Soung YH, et al. Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas. Oncogene. 2005;24(1):141-7.
129. Shivapurkar N, et al. Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther. 2002;1(1):65-9.
130. Harada K, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res. 2002;62(20):5897-901.
131. Pingoud-Meier C, et al. Loss of caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res. 2003;9(17):6401-9.
132. Sun T, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet. 2007;39(5):605-13.
133. Li C, et al. The six-nucleotide deletion/insertion variant in the CASP8 promoter region is inversely associated with risk of squamous cell carcinoma of the head and neck. Cancer Prev Res (Phila). 2010;3(2):246-53.
134. MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. Curr Opin Drug Discov Devel. 2010;13(5):568-76.
135. Chen L, et al. CD95 promotes tumour growth. Nature. 2010;465(7297):492-6.
136. Jing Y, et al. Tumor necrosis factor-alpha promotes tumor growth by inducing vascular endothelial growth factor. Cancer Invest. 2011;29(7):485-93.
137. Zhang M, et al. The roles of ROS and caspases in TRAIL-induced apoptosis and necroptosis in human pancreatic cancer cells. PLoS One. 2015;10(5), e0127386.
138. Vercammen D, et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med. 1998;187(9):1477-85.
139. Degterev A, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4(5):313-21.
140. Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1(2):112-9.
141. Cho YS, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137(6):1112-23.
142. Dondelinger Y, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014;7(4):971-81.
143. Galluzzi L, Kepp O, Kroemer G. MLKL regulates necrotic plasma membrane permeabilization. Cell Res. 2014;24(2):139-40.
144. Hildebrand JM, et al. Activation of the pseudokinase MLKL unleashes the four-helix bundle domain to induce membrane localization and necroptotic cell death. Proc Natl Acad Sci U S A. 2014;111(42):15072-7.
145. Murphy JM, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity. 2013;39(3):443-53.
146. Rodriguez DA, et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ. 2016;23:76-88.
147. Shin YK, Kim J, Yang Y. Switch for the necroptotic permeation pore. Structure. 2014;22(10):1374-6.
148. Su L, et al. A plug release mechanism for membrane permeation by MLKL. Structure. 2014;22(10):1489-500.
149. Oberst A, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3- dependent necrosis. Nature. 2011;471(7338):363-7.
150. Green DR, et al. RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. Mol Cell. 2011;44(1):9-16.
151. Feoktistova M, et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell. 2011;43(3):449-63.
152. Tenev T, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011;43(3):432-48.
153. Mandal P, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014;56(4):481-95.
154. Vanden Berghe T, et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15(2):135-47.
155. Linkermann A, et al. Two independent pathways of regulated necrosis mediate ischemiareperfusion injury. Proc Natl Acad Sci U S A. 2013;110(29):12024-9.
156. Kaiser WJ, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013;288(43):31268-79.
157. Thapa RJ, et al. Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc Natl Acad Sci U S A. 2013;110(33):E3109-18.
158. Linkermann A, et al. Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-alpha-induced shock. Mol Med. 2012;18:577-86.
159. Lukens JR, et al. RIP1-driven autoinflammation targets IL-1alpha independently of inflammasomes and RIP3. Nature. 2013;498(7453):224-7.
160. Lukens JR, et al. Dietary modulation of the microbiome affects autoinflammatory disease. Nature. 2014;516(7530):246-9.
161. Gurung P, et al. FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes. J Immunol. 2014;192(4):1835-46.
162. Philip NH, et al. Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-kappaB and MAPK signaling. Proc Natl Acad Sci U S A. 2014;111(20):7385-90.
163. Cullen SP, et al. Diverse activators of the NLRP3 inflammasome promote IL-1beta secretion by triggering necrosis. Cell Rep. 2015;11(10):1535-48.
164. Kearney CJ, et al. Necroptosis suppresses inflammation via termination of TNF- or LPS- induced cytokine and chemokine production. Cell Death Differ. 2015;22:1313-27.
165. Kaiser WJ, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471(7338):368-72.
166. Dillon CP, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell. 2014;157(5):1189-202.
167. Kaiser WJ, et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci U S A. 2014;111(21):7753-8.
168. Rickard JA, et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell. 2014;157(5):1175-88.
169. Yeh WC, et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science. 1998;279(5358):1954-8.
170. Yeh WC, et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity. 2000;12(6):633-42.
171. Zhang H, et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011;471(7338):373-6.
172. Newton K, Sun X, Dixit VM. Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol. 2004;24(4):1464-9.
173. Kelliher MA, et al. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 1998;8(3):297-303.
174. Dannappel M, et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature. 2014;513(7516):90-4.
175. Lee P, et al. Dynamic expression of epidermal caspase 8 simulates a wound healing response. Nature. 2009;458(7237):519-23.
176. Takahashi N, et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature. 2014;513(7516):95-9.
177. Roderick JE, et al. Hematopoietic RIPK1 deficiency results in bone marrow failure caused by apoptosis and RIPK3-mediated necroptosis. Proc Natl Acad Sci U S A. 2014;111(40):14436-41.
178. Liu P, et al. Dysregulation of TNFalpha-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012;26(6):1293-300.
179. Vucur M, et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep. 2013;4(4):776-90.
180. Schmidt SV, et al. RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1alpha release, and efficient paracrine dendritic cell activation. Oncotarget. 2015;6(11):8635-47.
181. Melo-Lima S, Celeste Lopes M, Mollinedo F. Necroptosis is associated with low procaspase- 8 and active RIPK1 and -3 in human glioma cells. Oncoscience. 2014;1(10):649-64.
182. Geserick P, et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 2015;6, e1884.
183. McCabe KE, et al. Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma. Cell Death Dis. 2014;5, e1496.
184. Oliver Metzig M, et al. Inhibition of caspases primes colon cancer cells for 5-fluorouracilinduced TNF-alpha-dependent necroptosis driven by RIP1 kinase and NF-kappaB. Oncogene. 2015 Nov 2. doi: 10.1038/onc.2015.398.
185. Moriwaki K, et al. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis. 2015;6, e1636.
186. Radogna F, Dicato M, Diederich M. Cancer-type-specific crosstalk between autophagy, necroptosis and apoptosis as a pharmacological target. Biochem Pharmacol. 2015;94(1):1-11.
187. Fulda S. Therapeutic exploitation of necroptosis for cancer therapy. Semin Cell Dev Biol. 2014;35:51-6.
188. Mohammad RM, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015;35:S78-103.
189. Takemura R, et al. PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol Res. 2015;3(8):902-14.
190. Yatim N, et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science. 2015;350(6258):328-34.